Immune cell attack: new hope for advanced kidney cancer?
NCT ID NCT06819293
First seen Apr 15, 2026 · Last updated May 14, 2026 · Updated 6 times
Summary
This early-phase study tests an experimental treatment called IB-T101 for adults with advanced clear cell kidney cancer. The therapy uses a patient's own immune cells (TILs) to fight the tumor. The main goals are to check safety and see if the treatment shrinks tumors. Only 12 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tongji hospital, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.